Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,358.76 | 3.33 | -0.04% |
| DAX 40 | 25,405.34 | 143.70 | 0.57% |
| Dow JONES (US) | 49,590.20 | 86.13 | 0.17% |
| FTSE 100 | 10,140.70 | 16.10 | 0.16% |
| HKSE | 26,744.55 | 136.07 | 0.51% |
| NASDAQ | 23,733.90 | 62.56 | 0.26% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,977.27 | 10.99 | 0.16% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,133.00 | 32.28 | -0.78% |